drugset
drugset / Trial / NCT06429566

Safety and Efficacy Study of GB001 Recombinant Peptide Spray in Subjects With Mild Recurrent Aphthous Ulcers

NCT06429566 ↗

Phase 2 Unknown 120 enrolled Zhejiang Echon Biopharm Limited
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This trial is conducted in China. The purpose is to evaluate the efficacy, Pharmacokinetics (PK) profile, immunogenicity and safety of GB001 recombinant peptide spray in adults with mild recurrent aphthous ulcer.

Timeline

Start
2023-07-18
Primary completion
2023-12-06
Completion
2026-07-10

Drugs

EvaluationDrugModalityDoseRoute
Subject GB001 Peptide 0.108 mg Oral
Subject GB001 Peptide 0.216 mg Oral

Indications

No indication recorded.